Unresectable Hepatocellular Carcinoma Global Market Report 2025

Description

Unresectable hepatocellular carcinoma refers to an aggressive tumor that commonly develops in conjunction with cirrhosis and chronic liver disease. Treatment options for unresectable hepatocellular carcinoma include surgical resection, liver transplant, ablation, and embolization.

The main types of unresectable hepatocellular carcinoma are primary, secondary, and benign liver growth. In this context, 'primary' signifies a greater significance, and as the most prevalent form of primary liver cancer, hepatocellular carcinoma is particularly noteworthy. Various treatment approaches, such as chemotherapy, molecularly targeted therapy, immunotherapy, and others, are employed in hospitals, specialty clinics, and cancer centers.

The unresectable hepatocellular carcinoma market research report is one of a series of new reports from The Business Research Company that provides unresectable hepatocellular carcinoma market statistics, including unresectable hepatocellular carcinoma industry global market size, regional shares, competitors with a unresectable hepatocellular carcinoma market share, detailed unresectable hepatocellular carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the unresectable hepatocellular carcinoma industry. This unresectable hepatocellular carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The unresectable hepatocellular carcinoma market size has grown marginally in recent years. It will grow from $1.98 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to chemotherapy advances, clinical trial outcomes, liver transplantation limitations, increased cancer cases, expanded access to therapies

The unresectable hepatocellular carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.95 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to healthcare policy changes, patient stratification strategies, real-world evidence utilization, patient advocacy and awareness, economic and dynamics. Major trends in the forecast period include precision medicine and biomarkers, real-world evidence and data integration, multidisciplinary approaches, global clinical trials and collaborations, and patient-centric care.

The rising prevalence of liver cancer is propelling the growth of the unresectable hepatocellular carcinoma market moving forward. Liver cancer occurs when healthy liver cells are overtaken by tumor cells that begin to grow uncontrollably. Unresectable hepatocellular carcinoma is a form of cancer that is treated through liver transplantation and radiofrequency ablation. For example, in October 2022, the Journal of Hepatology, a peer-reviewed scientific journal based in Switzerland, reported that globally, 830,200 individuals died from liver cancer in 2020, with an anticipated 1.4 million new liver cancer cases expected between 2020 and 2040, reflecting a 55.0% increase in new cases annually. Additionally, in January 2024, the American Cancer Society, a US-based non-profit organization, projected that around 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. in 2024 (28,000 in men and 13,630 in women), with approximately 29,840 deaths expected (19,120 men and 10,720 women). Therefore, the increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market.

The growth in healthcare expenditure is anticipated to drive the unresectable hepatocellular carcinoma market forward. Healthcare expenditure encompasses the total financial resources allocated to activities aimed at promoting, restoring, and maintaining health. As unresectable hepatocellular carcinoma progresses and becomes more complex, treatment options tend to become costlier. For example, in 2021, health spending experienced an average increase of approximately 6%, while a report by JPMorgan Chase & Co. in May 2022 revealed an overall 23% surge in healthcare spending in the same year. The growing healthcare expenditure is expected to be a significant driver in the expansion of the unresectable hepatocellular carcinoma market.

The increasing consumption of beer is anticipated to drive the growth of the unresectable hepatocellular carcinoma market moving forward. Beer consumption refers to the act of drinking beverages that contain ethyl alcohol, specifically beer. Excessive alcohol intake, including beer, is a well-recognized risk factor for developing hepatocellular carcinoma (HCC). Chronic alcohol use can harm liver cells, resulting in inflammation, fibrosis, and eventually cirrhosis, creating a conducive environment for HCC development. For instance, in December 2023, data published by Kirin Holdings Co. Ltd., a Japan-based company specializing in alcoholic and non-alcoholic beverages and pharmaceuticals, revealed that global beer consumption increased by approximately 5.4 million kiloliters in 2022, equivalent to about 8.5 billion bottles (633 ml each) compared to the previous year. Therefore, the rising beer consumption is contributing to the growth of the unresectable hepatocellular carcinoma market.

Innovations in products emerge as a notable trend gaining traction in the unresectable hepatocellular carcinoma market. Major companies operating in this market are actively pursuing the development of innovative products to maintain their market positions. For instance, AstraZeneca, a pharmaceutical and biotechnology company based in the UK, introduced Imjudo (tremelimumab) in combination with Imfinzi for unresectable liver cancer. This treatment, known as the STRIDE regimen, involves a single dose of anti-CTLA-4 antibody Imjudo 300mg combined with anti-PD-L1 antibody Imfinzi 1500 mg every four weeks. Patients receiving this combination showed a 22% lower chance of mortality compared to those receiving sorafenib.

Major players in the unresectable hepatocellular carcinoma market are focusing on the development of combination therapies to address the complexities of this condition. For example, Ono Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched Opdivo (nivolumab) Intravenous Infusion in combination with Yervoy in March 2023. Opdivo, a human anti-human PD-1 monoclonal antibody, works by blocking the interaction between PD-1 on T cells and its ligands on cancer cells, thereby enhancing T cells' ability to recognize and eliminate cancer cells more effectively. This development reflects the commitment of major companies to provide effective therapeutic options for unresectable hepatocellular carcinoma conditions.

Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.

North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the unresectable hepatocellular carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The unresectable hepatocellular carcinoma market includes revenues earned by entities by providing first-line agents, surgical resection, and liver transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Unresectable Hepatocellular Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on unresectable hepatocellular carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for unresectable hepatocellular carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The unresectable hepatocellular carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Primary; Secondary; Benign Liver Growth
2) By Treatment Type: Chemotherapy; Molecularly Targeted Therapy; Immunotherapy; Other Treatments
3) By End-Users: Hospitals; Specialty Clinics; Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer; Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma; Focal Nodular Hyperplasia; Hemangiomas
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F Hoffmann-La Roche Ltd.; Merck & Co Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25372

1. Executive Summary

2. Unresectable Hepatocellular Carcinoma Market Characteristics

3. Unresectable Hepatocellular Carcinoma Market Trends And Strategies

4. Unresectable Hepatocellular Carcinoma Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Unresectable Hepatocellular Carcinoma Growth Analysis And Strategic Analysis Framework

5.1. Global Unresectable Hepatocellular Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Unresectable Hepatocellular Carcinoma Market Growth Rate Analysis
5.4. Global Unresectable Hepatocellular Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Unresectable Hepatocellular Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Unresectable Hepatocellular Carcinoma Total Addressable Market (TAM)

6. Unresectable Hepatocellular Carcinoma Market Segmentation

6.1. Global Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary
Secondary
Benign Liver Growth
6.2. Global Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Molecularly Targeted Therapy
Immunotherapy
Other Treatments
6.3. Global Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Cancer Centers
6.4. Global Unresectable Hepatocellular Carcinoma Market, Sub-Segmentation Of Primary, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatocellular Carcinoma (HCC)
Fibrolamellar Carcinoma
Hepatoblastoma
6.5. Global Unresectable Hepatocellular Carcinoma Market, Sub-Segmentation Of Secondary, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metastatic Liver Cancer
Intrahepatic Cholangiocarcinoma
6.6. Global Unresectable Hepatocellular Carcinoma Market, Sub-Segmentation Of Benign Liver Growth, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatic Adenoma
Focal Nodular Hyperplasia
Hemangiomas

7. Unresectable Hepatocellular Carcinoma Market Regional And Country Analysis

7.1. Global Unresectable Hepatocellular Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Unresectable Hepatocellular Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Unresectable Hepatocellular Carcinoma Market

8.1. Asia-Pacific Unresectable Hepatocellular Carcinoma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Unresectable Hepatocellular Carcinoma Market

9.1. China Unresectable Hepatocellular Carcinoma Market Overview
9.2. China Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Unresectable Hepatocellular Carcinoma Market

10.1. India Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Unresectable Hepatocellular Carcinoma Market

11.1. Japan Unresectable Hepatocellular Carcinoma Market Overview
11.2. Japan Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Unresectable Hepatocellular Carcinoma Market

12.1. Australia Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Unresectable Hepatocellular Carcinoma Market

13.1. Indonesia Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Unresectable Hepatocellular Carcinoma Market

14.1. South Korea Unresectable Hepatocellular Carcinoma Market Overview
14.2. South Korea Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Unresectable Hepatocellular Carcinoma Market

15.1. Western Europe Unresectable Hepatocellular Carcinoma Market Overview
15.2. Western Europe Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Unresectable Hepatocellular Carcinoma Market

16.1. UK Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Unresectable Hepatocellular Carcinoma Market

17.1. Germany Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Unresectable Hepatocellular Carcinoma Market

18.1. France Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Unresectable Hepatocellular Carcinoma Market

19.1. Italy Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Unresectable Hepatocellular Carcinoma Market

20.1. Spain Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Unresectable Hepatocellular Carcinoma Market

21.1. Eastern Europe Unresectable Hepatocellular Carcinoma Market Overview
21.2. Eastern Europe Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Unresectable Hepatocellular Carcinoma Market

22.1. Russia Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Unresectable Hepatocellular Carcinoma Market

23.1. North America Unresectable Hepatocellular Carcinoma Market Overview
23.2. North America Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Unresectable Hepatocellular Carcinoma Market

24.1. USA Unresectable Hepatocellular Carcinoma Market Overview
24.2. USA Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Unresectable Hepatocellular Carcinoma Market

25.1. Canada Unresectable Hepatocellular Carcinoma Market Overview
25.2. Canada Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Unresectable Hepatocellular Carcinoma Market

26.1. South America Unresectable Hepatocellular Carcinoma Market Overview
26.2. South America Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Unresectable Hepatocellular Carcinoma Market

27.1. Brazil Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Unresectable Hepatocellular Carcinoma Market

28.1. Middle East Unresectable Hepatocellular Carcinoma Market Overview
28.2. Middle East Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Unresectable Hepatocellular Carcinoma Market

29.1. Africa Unresectable Hepatocellular Carcinoma Market Overview
29.2. Africa Unresectable Hepatocellular Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Unresectable Hepatocellular Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Unresectable Hepatocellular Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Unresectable Hepatocellular Carcinoma Market Competitive Landscape And Company Profiles

30.1. Unresectable Hepatocellular Carcinoma Market Competitive Landscape
30.2. Unresectable Hepatocellular Carcinoma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Unresectable Hepatocellular Carcinoma Market Other Major And Innovative Companies

31.1. Bristol-Myers-Squibb Company
31.2. Astrazeneca PLC
31.3. Takeda Pharmaceutical Company Limited
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Regeneron Pharmaceuticals Inc.
31.7. Chugai Pharmaceutical Co Ltd.
31.8. Eisai Co. Ltd.
31.9. Ipsen S.A.
31.10. Jiangsu HengRui Medicine Co. Ltd.
31.11. Exelixis Inc.
31.12. BeiGene Ltd.
31.13. Halozyme Therapeutics Inc.
31.14. Innovent Biologics Inc.
31.15. Sirtex Medical Limited

32. Global Unresectable Hepatocellular Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Unresectable Hepatocellular Carcinoma Market

34. Recent Developments In The Unresectable Hepatocellular Carcinoma Market

35. Unresectable Hepatocellular Carcinoma Market High Potential Countries, Segments and Strategies

35.1 Unresectable Hepatocellular Carcinoma Market In 2029 - Countries Offering Most New Opportunities
35.2 Unresectable Hepatocellular Carcinoma Market In 2029 - Segments Offering Most New Opportunities
35.3 Unresectable Hepatocellular Carcinoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer